Good loan buzz for Israeli drugmaker Teva Pharmaceutical
Israel-based Teva Pharmaceutical Industries has signed a $1.5bn three year revolving credit facility to refinance existing debt with improved terms.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
